Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 18,744 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Clostridium Difficile Infection
Interventions: RBX7455; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sarcoma, Clear Cell
Interventions: CPI-613 + Hydroxychloroquine; Drug
Lead sponsor: Cornerstone Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Duarte, California • Kansas City, Kansas • Ann Arbor, Michigan + 5 more

Conditions: Recurrent Prostate Carcinoma
Interventions: High-Dose Rate Brachytherapy, Hyperthermia Treatment, Laboratory Biomarker Analysis; Radiation · Procedure · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: cetuximab, gemcitabine hydrochloride, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Breast Cancer
Interventions: IDC-G305; Biological
Lead sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more

Conditions: Neurological Disorder
Interventions: Glyceryl Tribenzoate; Drug
Lead sponsor: Forest Hills Lab; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bloomfield, New Jersey

Conditions: Prostatic Neoplasms
Interventions: JNJ-75229414, Bridging Therapy; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Duarte, California • Louisville, Kentucky • Minneapolis, Minnesota + 4 more

Conditions: HIV Infections
Interventions: VRC07-523LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anemia, Iron Deficiency
Interventions: Ferric maltol capsule, Ferric maltol suspension; Drug
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Myeloid Leukemia, in Relapse, MDS
Interventions: MT-401-OTS; Drug
Lead sponsor: Marker Therapeutics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Duarte, California • Tampa, Florida • Kansas City, Kansas

Conditions: Alopecia Areata
Interventions: Ritlecitinib 20 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 9
States / cities: Encinitas, California • Coral Gables, Florida • Miami, Florida + 5 more

Conditions: Healthy
Interventions: LY3537982, [¹⁴C]-LY3537982; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Severe Combined Immunodeficiency
Interventions: AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Months and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2038
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ECTEINASCIDIN 743; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 42
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 34 more

Conditions: Breast Cancer, Lymphoma
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 100 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more

Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Refractory Chronic Myelomonocytic Leukemia, CMML, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemias, Refractory Acute Myeloid Leukemia (AML), Acute Monocytic Leukemia
Interventions: STX-0712; Biological
Lead sponsor: Solu Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Stanford, California • Tampa, Florida • Boston, Massachusetts + 4 more

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Allografting, Survey Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Advanced Cancers
Interventions: Azacitidine, Valproic Acid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Graft Versus Host Disease
Interventions: total nodal irradiation, laboratory biomarker analysis, questionnaire administration; Radiation · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cancer
Interventions: relatlimab, nivolumab, rHuPH20; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
Interventions: Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Interventions: Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation

PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

A Study of [14C]-LY3537982 in Healthy Participants

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Autologous Gene Therapy for Artemis-Deficient SCID

Ecteinascidin 743 in Treating Children With Refractory Solid Tumors

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1